Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL)
Exelixis (EXEL) recently faced removal from Russell 1000 defensive indexes and reported mixed zanzalintinib trial results, showing a statistically significant overall survival benefit in the full population but a non-significant trend in a key subgroup. These developments, coupled with an analyst downgrade due to pipeline uncertainty, intensify focus on the FDA's December 2026 decision for zanzalintinib as Exelixis seeks to diversify beyond CABOMETYX. Investors now need to critically evaluate the company's ability to build a second growth pillar and manage pipeline risks.
ETFs Investing in Exelixis, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Exelixis, Inc., a pharmaceutical company. The ETFs are sorted by their market value and include details such as weight of Exelixis in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify investment opportunities in Exelixis through diversified ETF holdings.
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL
This article provides a brief overview of Exelixis, Inc. (NASDAQ: EXEL)'s financial information, specifically focusing on its price-to-sales forward metric. It indicates that the content was "Made by humans" and clarifies market data sources.
Exelixis, Inc. (EXEL) Stock Price Today
This page provides real-time stock price information for Exelixis, Inc. (EXEL), including its current price of 545.49 kr, a 24-hour trading volume of 0 kr, and a market capitalization of 137.11B kr. The stock has seen a 3.5% movement in the last day. The page also features a "Price Performance" section with 24-hour low and high values and lists other popular real-world assets.
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says
UBS has initiated coverage on Exelixis (EXEL) with a Neutral rating, citing a balanced risk-reward profile ahead of crucial clinical data readouts. The analysis highlights an attractive valuation in the mid-$20s, but notes potential headwinds from competitors and pipeline trial risks. Key upcoming catalysts include results from STELLAR-303 and STELLAR-304 studies, crucial for Cabometyx's expansion into new indications.
UBS raises Exelixis stock price target to $52 on pipeline outlook
UBS has increased its price target for Exelixis Inc. (NASDAQ:EXEL) shares to $52 from $43, maintaining a Neutral rating, citing the company's pipeline outlook, including a non-clear cell renal cell carcinoma readout and a colorectal cancer launch. Despite recent setbacks for competitors and in the STELLAR-303 trial, Exelixis stock has performed well, returning 23% year-to-date and trading above the new target at $54.45. UBS anticipates success for zanzalintinib in upcoming data readouts and highlights 2027 revenues as a key catalyst.
UBS raises Exelixis stock price target to $52 on pipeline outlook
UBS has increased its price target for Exelixis Inc. (NASDAQ:EXEL) to $52 from $43, while maintaining a Neutral rating, citing a balanced risk-reward profile ahead of key pipeline catalysts. Despite the stock already exceeding this new target at $54.45 and approaching its 52-week high, UBS sees further potential, particularly from a successful non-clear cell renal cell carcinoma readout for zanzalintinib. This comes amidst mixed trial results for STELLAR-303 but strong year-to-date performance and an "EXCELLENT" financial health rating according to InvestingPro.
UBS raises Exelixis stock price target to $52 on pipeline outlook By Investing.com
UBS has increased its price target for Exelixis Inc. (NASDAQ:EXEL) shares to $52 from $43, while maintaining a Neutral rating, due to upcoming catalysts and pipeline outlook. The stock is currently trading above this target near its 52-week high. Key factors include the potential success of zanzalintinib in non-clear cell renal cell carcinoma and its expansion into other indications to maintain value post-loss of exclusivity for cabozantinib.
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Aftab Dana
This document is a statement of changes in beneficial ownership of securities for Exelixis. It specifically pertains to officer Aftab Dana and records alterations in his beneficial ownership of the company's securities.
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $56 price target for Exelixis (NASDAQ:EXEL) following the detailed results from the phase 3 STELLAR-303 pivotal trial. Despite a non-statistically significant trend in overall survival from the trial, the firm believes these results will not hinder potential FDA approval for zanzalintinib plus Tecentriq. Exelixis shares are trading near their 52-week high, up 23% year-to-date, and are considered undervalued with an "EXCELLENT" financial health score by InvestingPro.
UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating
UBS has increased its price target on Exelixis (EXEL) from $43 to $52, while maintaining a Neutral rating on the stock. This adjustment comes ahead of key catalysts for the biotechnology company. Exelixis specializes in oncology, with its flagship molecule cabozantinib and investigational asset zanzalintinib.
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug?
Truist analyst Gregory Renza downgraded Exelixis (EXEL) to Hold from Buy with a $54 price target, citing pipeline uncertainty regarding zanzalintinib, its next-generation cancer drug. While the FDA is reviewing zanzalintinib for metastatic colorectal cancer, Renza highlighted that regulatory approval doesn't guarantee commercial success and key clinical data readouts are still pending. Exelixis's current lead product, cabozantinib, drives most of its revenue.
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Value-Defensive Index
Exelixis, Inc. (NasdaqGS: EXEL) has been dropped from the Russell 1000 Value-Defensive Index. This news was published on June 29, 2026, at 09:47 am EDT. The article also mentions the company's recent activities, including presentations at healthcare conferences and updates on its clinical trials.
Enterprise value to EBITDA forward of Exelixis, Inc. – NASDAQ:EXEL
This article provides the enterprise value to EBITDA forward for Exelixis, Inc. (NASDAQ: EXEL). It appears to be a financial data point from TradingView, focusing on a specific valuation metric for the pharmaceutical company. The content primarily lists navigation and footer information, with the core data point being "Enterprise value to EBITDA forward of Exelixis, Inc." followed by a period value.
Enterprise value to EBITDA forward of Exelixis, Inc. – GETTEX:EX9
The article focuses on the enterprise value to EBITDA forward for Exelixis, Inc. (GETTEX:EX9). It provides a brief financial overview within the context of market data and financial reporting, indicating that the market is currently closed with no trades.
Exelixis stock reaches all-time high of 53.97 USD
Exelixis (EXEL) stock has reached a new all-time high of $53.97, trading slightly below its 52-week high, and is considered undervalued according to InvestingPro analysis. The biotechnology firm has seen a 22.46% increase over the past year, supported by positive drug pipeline developments and analyst upgrades. Despite mixed results in some trials, the company continues to expand its market presence and enhance shareholder value.
Exelixis stock reaches all-time high of 53.97 USD By Investing.com
Exelixis Inc. (EXEL) stock hit an all-time high of $53.97, just shy of its 52-week high, and is considered undervalued according to InvestingPro. The biotech firm has seen a 22.46% increase over the past year, driven by drug pipeline advancements and strategic partnerships, with analysts revising earnings forecasts upwards. Recent mixed results from clinical trials and varied analyst ratings reflect ongoing developments for the company.
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Actuals & Estimates (BMFBOVESPA:E2XE34)
This page provides financial actuals and estimates for Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:E2XE34) on TradingView. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and features trend visualization over time.
Enterprise value to revenue forward of Exelixis, Inc. – NASDAQ:EXEL
The article provides the enterprise value to revenue forward for Exelixis, Inc. (NASDAQ: EXEL). It presents financial data related to the company, noted as being made by humans and offering various financial metrics and information on TradingView.
Liquidity Mapping Around (EXEL) Price Events
This article provides a liquidity mapping analysis for Exelixis Inc. (NASDAQ: EXEL). It outlines neutral near and mid-term readings, a positive long-term bias, and details institutional trading strategies including position, momentum breakout, and risk hedging strategies. The analysis identifies key support and resistance levels across multiple timeframes.
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
This page provides financial information for Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (E2XE34) on TradingView, specifically focusing on its enterprise value to revenue forward. The article mentions that market is closed with no trades. It also touches upon general market data and copyright information from various financial data providers.
EX9 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Exelixis, Inc. (EX9) stock, outlining analyst price targets, current stock performance, and key financial data. It includes information on market capitalization, earnings reports, revenue, net income, and employee count. The article also touches on technical analysis ratings and historical stock performance.
Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty
Truist Securities has initiated coverage on Exelixis Inc. with a Hold rating and a $54.00 price target, citing pipeline uncertainty. The biopharmaceutical company's stock currently trades near its 52-week high, and its leading drug Cabometyx faces patent expiration in 2031, while a next-generation drug, zanzalintinib, recently missed its overall survival topline in a non-small cell lung cancer trial. Despite some setbacks, Exelixis continues to advance its cancer treatment options through ongoing research and partnerships.
Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty
Truist Securities has initiated coverage on Exelixis Inc. with a Hold rating and a $54.00 price target, citing pipeline uncertainty despite the stock appearing undervalued by InvestingPro analysis. The biopharmaceutical company faces challenges including the upcoming loss of exclusivity for Cabometyx in 2031 and recent mixed trial results for its next-generation drug zanzalintinib, though it continues to pursue new partnerships and research in cancer treatment.
Price to earnings forward of Exelixis, Inc. – NASDAQ:EXEL
This article provides access to the "Price to earnings forward" financial data for Exelixis, Inc. (NASDAQ: EXEL) on the TradingView platform. It appears to be a direct link to a specific financial metric for the company, accessible within the platform's detailed financial overview. The content primarily consists of navigation and platform information surrounding this data point.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Exelixis's shares dropped after the STELLAR-303 study for its drug zanzalintinib in combination with Roche's Tecentriq showed disappointing results in a subset of colorectal cancer patients without active liver metastases, failing to meet a statistically significant overall survival endpoint. Despite this, the study had previously met its overall survival endpoint in the broader patient population, and the drug's New Drug Application is currently under review by the FDA with a target action date of December 3, 2026. Exelixis is also collaborating with Merck on additional studies for zanzalintinib to expand its potential applications.
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Exelixis announced the final analysis results from the dual primary endpoint of overall survival (OS) in a subset of patients without active liver metastases (NLM) from the phase 3 STELLAR-303 trial. The trial evaluated zanzalintinib in combination with atezolizumab versus regorafenib in previously treated non-MSI-high metastatic colorectal cancer, showing a non-statistically significant trend favoring the combination in the NLM subpopulation. The U.S. FDA has accepted the New Drug Application for zanzalintinib in combination with atezolizumab for mCRC, with a target action date of December 3, 2026.
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst
Exelixis reported final overall survival data from its Phase 3 STELLAR-303 trial, which showed a numerical but not statistically significant overall survival benefit for the investigational combination of zanzalintinib and atezolizumab in a subgroup of metastatic colorectal cancer patients. Despite the lack of statistical significance, analyst William Blair commented that Exelixis offers a "highly defensive investment profile" due to its substantial cash flow generation. The FDA is currently reviewing the New Drug Application for zanzalintinib, with a target action date of December 3, 2026.
Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints
Exelixis shares are down after the company announced that a final analysis of one of its phase 3 dual primary endpoints for zanzalintinib in metastatic colorectal cancer failed to meet statistical significance. The trial, STELLAR-303, involved thousands of patients and aimed to assess the efficacy of zanzalintinib. This outcome has led to a negative market reaction for Exelixis.
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Exelixis announced the final analysis results from the phase 3 STELLAR-303 trial for zanzalintinib in combination with atezolizumab in metastatic colorectal cancer patients without active liver metastases. While showing a non-statistically significant trend in overall survival favoring the combination in this subgroup, the trial previously met its dual primary endpoint of statistically significant improvement in overall survival in the overall ITT population. The FDA has accepted a New Drug Application for the combination with a target action date of December 3, 2026.
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Exelixis Inc (EXEL), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected EPS and revenue for upcoming quarters and compares EXEL's analyst ratings to its peers in the Biotechnology & Medical Research industry. The overall sentiment from analysts leans towards a "Buy" trend.
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis
Exelixis Inc (EXEL) demonstrates robust financial health with a score of 8.96, ranking 21st in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 9.97% to $610.81M and a net profit increase of 31.86%. This strong performance reflects high operating efficiency and growth potential.
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Exelixis Inc's (EXEL) shareholder structure, listing major institutional holders and their proportion of shares. It details shareholder types, institutional shareholding trends over recent quarters, and individual shareholder activity with changes in holdings for key firms. The report also includes related ETF holdings.
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing its income by business segments and geographical regions. As of April 6, 2025, CABOMETYX is the primary revenue driver, contributing 91.09% of the total, with the U.S. market dominating regional revenue at 92.25%. The data covers fiscal years up to FY2025, detailing contributions from products like CABOMETYX and COMETRIQ, as well as license and collaboration service revenues.
Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results
Exelixis Inc reported its first-quarter 2024 financial results, showing revenue growth driven primarily by its flagship cancer drug, Cabometyx. The company also provided an updated 2024 financial outlook, projecting continued revenue growth despite increased R&D spending to further develop its clinical pipeline and lifecycle management strategy. Investors are watching how the company balances profitability from Cabometyx with aggressive investment in new therapies.
Why (EXEL) Price Action Is Critical for Tactical Trading
This article from Stock Traders Daily discusses the critical price action of Exelixis Inc. (NASDAQ: EXEL) for tactical trading, based on AI-driven analysis. It highlights strong sentiment across all time horizons, indicating an overweight bias, and identifies potential upside. The report outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions
Exelixis reported positive phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors, demonstrating significant improvement in progression-free survival. This extends the potential reach of CABOMETYX, but given the stock's strong performance, investors are evaluating the impact on its already meaningful valuation. Regulatory responses and a recent surge in insider selling are key considerations for investors.
Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL
Goldman Sachs Group Inc. significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, purchasing over 1.1 million additional shares, raising its total holding to 2.1 million shares valued at approximately $92.7 million. Following this news, Exelixis shares rose by 2.4% and opened near their 52-week high, supported by strong earnings results. Despite mixed analyst sentiment, with an average "Hold" rating, several firms have recently raised their price targets for the biotechnology company.
Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL
Cibc World Market Inc. significantly increased its stake in Exelixis, Inc. by 462.3% in the fourth quarter, adding 31,985 shares to hold a total of 38,904 shares valued at $1.705 million. This move is part of a broader trend, with other institutional investors also boosting their positions, leading to 85.27% of Exelixis shares being institutionally owned. Exelixis reported strong earnings with EPS of $0.87 and revenue of $610.81 million, surpassing estimates, while analysts currently rate the stock as "Hold" with a target price of $47.35.
BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL
BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Exelixis, Inc. by 74.9% in the fourth quarter, now holding 43,658 shares valued at approximately $1.91 million. This comes as several insiders, including CFO Christopher J. Senner and Director Sue Gail Eckhardt, sold over $10 million worth of shares. Despite insider selling, Exelixis reported strong quarterly results with earnings of $0.87 per share on $610.81 million revenue, exceeding expectations, and currently holds a consensus "Hold" rating from analysts.
Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL
Bank of New York Mellon Corp reduced its stake in Exelixis, Inc. by 12.3% during the fourth quarter, selling 285,584 shares. Despite this, other institutional investors like Goldman Sachs Group Inc. and BNP Paribas Financial Markets increased their holdings significantly. Exelixis reported strong first-quarter earnings, beating analyst estimates, and the company currently holds an average "Hold" rating from analysts with an average price target of $47.35.
Exelixis stock hits all-time high at 52.98 USD By Investing.com
Exelixis Inc. (EXEL) stock reached an all-time high of $52.98, reflecting a 24.86% increase over the past year. The biotechnology company, currently valued at $13.34 billion, shows an attractive P/E ratio of 17.08 and a PEG ratio of 0.42, suggesting undervaluation and strong near-term earnings growth potential. Recent positive developments include exceeding Q1 2026 earnings and revenue expectations, a new collaboration with Merck for a phase 3 trial, and promising data from the phase 3 CABINET trial for cancer treatment.
Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co.
Northwestern Mutual Wealth Management Co. significantly increased its stake in Exelixis, Inc. by 2,920.5% in the fourth quarter, now owning 25,040 shares valued at $1.1 million. This increase comes as Exelixis reported strong quarterly results, beating EPS estimates with $0.87 and achieving a 10% year-over-year revenue increase. Despite recent insider share sales by directors, analysts currently maintain a "Hold" rating for the stock with a consensus target price of $47.35, and institutional investors own 85.27% of the stock.
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth
Exelixis, Inc. (EXEL) is highlighted as a significant player in the biotechnology sector, specializing in cancer treatments with products like CABOMETYX and COMETRIQ. The company demonstrates strong financial performance with 10% year-over-year revenue growth and a High ROE of 40.99%, indicating efficient use of shareholder funds and profitability. Despite a mixed analyst sentiment and a slight potential downside from its current price, its robust pipeline, significant free cash flow, and strategic collaborations position it as a compelling investment opportunity for future growth in oncology therapeutics.
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations
Exelixis, Inc. reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors, showing significant improvements in progression-free survival regardless of tumor functional status. These results expand the clinical evidence for CABOMETYX and reinforce its potential as a broad neuroendocrine tumor option, impacting investor considerations for EXEL stock which has seen strong returns. The article discusses both the clinical implications for physicians and the financial implications for investors, highlighting the growing oncology reach of Exelixis while also noting the concentration risk in a single drug.
Exelixis director Sue Eckhardt sells $491,973 in stock
Exelixis director Sue Eckhardt sold 9,812 shares of the company's common stock for $491,973 on June 1, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, though InvestingPro analysis suggests it is still undervalued with excellent financial health. Following the transaction, Ms. Eckhardt directly holds 16,079 shares, including RSUs.
Exelixis director Jack Wyszomierski sells $198,408 in shares
Jack L. Wyszomierski, a director at Exelixis Inc. (NASDAQ:EXEL), recently sold 3,925 shares of the company's common stock for $198,408. This transaction was executed under a Rule 10b5-1 trading plan. The article also notes Exelixis' strong financial performance in Q1 2026 and its collaboration with Merck for a new clinical trial.
EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a detailed financial analysis of Exelixis Inc (EXEL), outlining its revenue breakdown, profitability margins, and a comparison with key competitors RGC and MDGL. It highlights that CABOMETYX is the primary revenue driver, contributing 90.3% of total sales, and details EXEL's strong gross, operating, and net margins, alongside a robust Return on Equity. The article concludes by benchmarking EXEL's market capitalization and efficiency against its peers.
[144] EXELIXIS, INC. SEC Filing
This SEC filing refers to a Form 144 filed by Exelixis, Inc. (EXEL) on June 1, 2026, indicating a proposed sale of securities. The document outlines the information required for such a sale under Rule 144, including details about the securities to be sold (9812 shares of common stock with an aggregate market value of $499,136.44) and the acquisition nature (restricted stock unit from the issuer). The filing has a neutral impact and sentiment according to StockTitan.
Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL)
Jack Wyszomierski, a Director at Exelixis Inc (EXEL), sold 3,925 shares of the company on June 1, 2026, increasing his total sales over the past year to 103,499 shares. Exelixis, a biotechnology company focused on cancer treatments, has seen 1 insider buy and 21 insider sells in the last year. The stock is currently trading at $50.55, with a price-to-GF-Value ratio of 1.21, suggesting it is modestly overvalued.
